Prophylaxis and therapy of mouse mammary carcinomas with doxorubicin and vincristine encapsulated in sterically stabilised liposomes

In vitro ultrasound-mediated leakage from phospholipid vesicles

“…Cancer drugs such as doxorubicin and vincristine have already been encapsulated within polymeric micelles [27,47]. Recent studies have also indicated that PEGylated liposomes are more ''susceptible'' to ultrasound [28].…”

“…Moreover, within certain cholesterol composition ranges, multiple phases (liquid-ordered and liquid-disordered) coexist in the membrane [56,57]. Such multiple phases also exist in cell membranes, giving rise to cholesterol-rich domains termed ''lipid rafts'' [47,58]. The interfacial tensions of these multiple phases are likely to be different, and the results of this study would therefore suggest that ultrasound-induced leakage occurs either preferentially within cholesterol-rich regions of the bilayer or on the border of these regions.…”

Encapsulation in Cationic Liposomes Enhances Antitumour Efficacy and Reduces the Toxicity of Etoposide, a Topo-Isomerase II Inhibitor

“…In preliminary experiments, we had observed an enhancement in the efficacy of etoposide against choriocarcinoma following liposome-mediated delivery [18]. Similar observations have also been noted with other antineoplastic drugs such as vincristine [25], doxorubicin [26] and taxol [27]. However, most of these formulations utilised sterically stabilised long-circulating liposomes, which attain higher concentrations in the tumour than conventional liposomes.…”

Liposomally targeted cytotoxic drugs for the treatment of cancer

“…The formulation that has become Caelyx}Doxil has been shown to exert signi® cant activity against a broad range of syngeneic and xenograft tumours in rodent models. In general, these eOE ects have been shown to exceed those of comparable conventional liposomal formulations, with appreciable amelioration of treatment-related toxicity (Gabizon 1992 ;Huang et al 1992a ;Vaage et al 1992Vaage et al , 1993aVaage et al , b, 1994Vaage et al , 1995Vaage et al , 1997Williams et al 1993 ;Siegal et al 1995 ;Cabanes et al 1998b ;Harrington et al 2000c).…”

“…Studies have been performed with vincristine (Allen et al 1995 ;Vaage et al 1993a), mitoxantrone (Chang et al 1997) and platinum analogues (Mori et al 1996 ;Newman et al 1999 ;Vaage et al 1999 ;Harrington et al 2000c). In the case of vincristine and mitoxantrone, liposomal encapsulation was shown to signi® cantly increase their antitumour activity, while, for vincristine, reducing the toxicity of treatment.…”